Delta plus variant and anticovid pill, Ema news

Delta plus variant and the anticovid pill are among the topics on the EMA agenda that takes stock of the coronavirus emergency. DELTA PLUS VARIANT – Spotlight on the Delta Plus variant, the latest covid threat that has come to the fore and is now also being watched by Ema, the European Medicines Agency. “We are all looking at” the variant situation of Sars-CoV-2 with winter approaching, “to try to understand where the virus is going and what we might expect in the weeks and months to come. Delta is still the dominant strain. is circulating “, and” we are beginning to see that there are some additional mutations taking place “at the moment” in a few cases on the Delta variant. We have heard of the “new mutation” AY.4.2 “, which is a of ‘special observations’ for example in Gb where the cases in which it has been sequenced are increasing, “and we must monitor very closely”, says Marco Cavaleri, head of Vaccines and Therapeutic Products for Covid-19 of the European Drug Agency Ema , answering a question about the upcoming winter season during the periodic press briefing organized by the EU regulatory body. It is necessary to monitor, he explains, “because what could happen is that the backbone of the variant remains, but further mutations arrive and it could also be something that gives greater transmissibility or some kind of immune escape”, that is the ability of the virus to escape the immunity. “It is important that we continue this work globally, together not only with European public authorities, but also outside Europe with the World Health Organization. WHO is now making several efforts to develop a good system that can do surveillance and quickly lead to decisions regarding new variants “. ANTICOVID PILL – The Agency is expected to begin “next week” the evaluation of the oral antiviral drug molnupiravir developed by the American Merck, which has been shown to reduce the risk of hospitalization and death in patients with mild or mild Covid by about 50%. moderate. “The EMA – explained at the press conference Marco Cavaleri, head of Vaccines and Therapeutic Products for Covid-19 of the EU regulatory body – has constantly talked with the developer” of the product, described by experts as the hope of a first anti-home treatment SARS-CoV-2. “We expect the rolling review procedure to begin next week,” Cavaleri announced.